电子阿尔伯塔卒中项目早期CT评分软件在ENCHANTED试验数据库中的临床效用
在ENCHANTED试验接受阿替普酶治疗的急性缺血性卒中患者中,评估电子阿尔伯塔卒中项目早期CT评分(e-ASPECTS)的临床效用。1480例(61%)薄层CT扫描纳入分析,e-ASPECTS中位数9分,较低e-ASPECTS与基线神经功能严重程度及90天不良结局独立相关,对症状性颅内出血的预测未达统计学显著。
要点
- e-ASPECTS中位数9分,77%患者评分良好(8-10分)。
- e-ASPECTS每降低1分,90天死亡或残疾的调整OR为0.91。
- e-ASPECTS对症状性颅内出血的调整OR为0.87,未达统计学显著。
核心结论
- 薄层CT(≤6 mm)获得的e-ASPECTS评分与基线神经功能严重程度高度相关,并可独立预测急性缺血性卒中患者的功能恢复和不良结局。
研究设计与样本
- 回顾性分析随机对照试验ENCHANTED(强化降压与溶栓治疗卒中研究)阿替普酶剂量组中前循环急性缺血性卒中患者的基线非增强CT扫描。
- 排除图像质量差和层厚大于6 mm的扫描,最终1480例(61%)扫描纳入e-ASPECTS分析。
- 采用多变量逻辑回归模型评估e-ASPECTS对残疾结局和症状性颅内出血的预测能力。
主要发现
- e-ASPECTS评分中位数为9分(四分位距8-10),77%的患者评分良好(范围8-10)。
- e-ASPECTS评分每降低1分,与基线美国国立卫生研究院卒中量表评分升高显著相关(r=-0.31,P<0.0001)。
- e-ASPECTS评分每降低1分,与90天不良结局(改良Rankin量表评分2-6)显著相关(r=-0.27,P<0.001)。
- 调整后,e-ASPECTS每降低1分对应的90天结局比值比:死亡或残疾(改良Rankin量表评分2-6)为0.91(95%CI 0.85-0.97),死亡和严重残疾(改良Rankin量表评分3-6)为0.89(95%CI 0.83-0.95),死亡为0.86(95%CI 0.79-0.95)。
- 根据溶栓后卒中监测研究标准定义的症状性颅内出血,e-ASPECTS每降低1分的调整比值比为0.87(95%CI 0.72-1.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Clinical utility of electronic Alberta Stroke Program Early CT Score (e-ASPECTS), an automated system for quantifying signs of infarction, was evaluated in a large database of thrombolyzed patients with acute ischemic stroke. METHODS: All baseline noncontrast computed tomographic scans of patients with anterior circulation acute ischemic stroke who participated in the alteplase dose arm of the randomized controlled trial ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) were reviewed; poor quality and large (>6 mm) slice thickness were excluded. Included scans had e-ASPECTS scores correlated with baseline neurological severity (National Institutes of Health Stroke Scale scores) and 90-day disability outcomes (modified Rankin Scale scores). Multivariable logistic regression models were used to determine the predictive ability of e-ASPECTS for disability outcomes and symptomatic intracranial hemorrhage. RESULTS: Of 2426 available computed tomographic images, 1480 (61%) were included in analyses of e-ASPECTS scores (median 9 [interquartile range, 8-10], 77% with good [range, 8-10] scores). Lower e-ASPECTS scores (per 1-point decrease) were significantly associated with increasing baseline National Institutes of Health Stroke Scale scores (r, -0.31; P<0.0001) and 90-day poor outcome (modified Rankin Scale scores, 2-6; r, -0.27; P<0.001). Adjusted odds ratios and 95% confidence intervals for 90-day outcomes were death or disability (modified Rankin Scale scores, 2-6; 0.91 [0.85-0.97]), death and major disability (modified Rankin Scale scores, 3-6; 0.89 [0.83-0.95]), and death (0.86 [0.79-0.95]); and for symptomatic intracranial hemorrhage, according to the Implementation of Thrombolysis in Stroke-Monitoring Study criteria was 0.87 (0.72-1.05). CONCLUSIONS: e-ASPECT scores from thin computed tomographic slices (≤6 mm) were highly correlated with baseline neurological severity and independently predict functional recovery and adverse outcomes in acute ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01422616.
引用
- Nagel S, Wang X, Carcel C, et al. Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database. Stroke. 2018. PMID: 29777016. doi:10.1161/STROKEAHA.117.019863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。